Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Griesinger

Showing results (101-110 of 159) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 8, 2022
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysisNikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access programNikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, et al.
Cancers|September 9, 2022
Differences in Stakeholders' Perception of the Impact of COVID-19 on Clinical Care and Decision-MakingJoerg Haier, Johannes Beller, Kristina Adorjan, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Cancers|December 23, 2022
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP CohortsChristos Chouaid, Michael Thomas, Didier Debieuvre, et al.
Future Oncology (London, England)|February 25, 2025
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiativeSøren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, et al.
JTO Clinical and Research Reports|April 13, 2026
Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief ReportMaximilian Rost, Rieke Fischer, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)Michael Kreuter, Johan Vansteenkiste, Jürgen R Fischer, et al.
Pageof 16

Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|July 8, 2022
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysisNikolaj Frost, Julia Roeper, Janna-Lisa Velthaus, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access programNikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero, et al.
Cancers|September 9, 2022
Differences in Stakeholders' Perception of the Impact of COVID-19 on Clinical Care and Decision-MakingJoerg Haier, Johannes Beller, Kristina Adorjan, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2022
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgeryTobias Boch, Nikolaj Frost, Linna Sommer, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Cancers|December 23, 2022
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP CohortsChristos Chouaid, Michael Thomas, Didier Debieuvre, et al.
Future Oncology (London, England)|February 25, 2025
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiativeSøren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, et al.
JTO Clinical and Research Reports|April 13, 2026
Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief ReportMaximilian Rost, Rieke Fischer, Martin Reck, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study)Michael Kreuter, Johan Vansteenkiste, Jürgen R Fischer, et al.
Pageof 16